Year :
2024
| Month :
April
| Volume :
18
| Issue :
4
| Page :
RE01 - RE06
Full Version
Narrative Review on Osteoporosis: A Silent Killer
Published: April 1, 2024 | DOI: https://doi.org/10.7860/JCDR/2024/69058.19248
Shrihari L Kulkarni, Harpreet Kour
1. Professor, Department of Orthopaedics, SDM Medical College and Hospital, Shri Dharmasthala Manjunatheshwara University, Dharward, Karnataka, India.
2. Associate Professor, Department of Physiology, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India.
Correspondence Address :
Dr. Harpreet Kour,
Associate Professor, Department of Physiology, Jawaharlal Nehru Medical College, KAHER, Nehru Nagar, Belagavi-590010, Karnataka, India.
E-mail: harpreetkour.kour@gmail.com
Abstract 
Osteoporosis is a common condition affecting the elderly population. Most of the time, it is diagnosed only after an individual suffers from a fracture. In addition to the fracture and its complications, the patients and their families must also bear the psychological and financial consequences of the disease. There are multiple risk factors associated with osteoporosis, hence it requires a multimodal approach in management as well. This narrative review aims to provide a comprehensive insight into the classification, prevalence, pathophysiology, signs and symptoms, risk factors, screening tools, management, differential diagnosis, prognosis, complications, and recent advances in osteoporosis.
Keywords
Age related bone loss, Bone mineral density, Male osteoporosis, Postmenopausal osteoporosis
Introduction
Osteoporosis means porous bones with decreased Bone Mineral Density (BMD), disrupted bone microarchitecture, and altered protein arrangements in the bone. The World Health Organisation (WHO) has defined osteoporosis as a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture (1),(2).
Definition
As per BMD classification, a t-score is calculated. A t-score is a statistical test that measures Standard Deviation (SD) from the mean. A t-score of one SD is a normal score and is usually found in young adults (sex-matched 30-year-old). The WHO has a t-score for BMD. The t-score between -1 and -2.5 is known as osteopenia, i.e., low bone mass, and scores below -2.5 as osteoporosis (3). Osteoporosis is considered a silent menace because it progresses without any significant signs and symptoms until any fractures occur (4). Normally, the inside of the bone is like a honeycomb with compactly arranged osteocytes. In osteoporosis, the space between the bone cells increases, and the walls of the honeycomb also get thinner, which makes the bone weak and prone to fractures just due to minor fragility fractures, hence making bone density a major determinant of fracture risk (5),(6).
An imbalance in the physiological processes of bone resorption and bone remodeling with decreased skeletal mass relates to osteoporosis. The bone mass peaks at about the third decade of life, followed by a period of bone resorption that exceeds bone formation. In histologic specimens, adults with osteoporosis exhibit significantly reduced thickness of trabeculae, smaller osteon size, and enlargement of both Haversian canals and marrow spaces (7),(8).
Classification of Osteoporosis
There are mainly two types of osteoporosis:
1. Primary osteoporosis: It occurs as a part of the ageing process and according to a decrease in hormone levels in the body. As age progresses, the microstructure of the bones degrades, and BMD decreases, leading to an increased risk of fractures.
2. Secondary osteoporosis: It occurs due to secondary causes, including various medications used in the treatment of diseases including hyperparathyroidism, hyperthyroidism, anorexia nervosa, malabsorption syndrome, chronic renal failure, and Cushing syndrome. Conditions leading to long-term immobilisation can also result in secondary osteoporosis. Long-standing secondary amenorrhoea due to non oestrogen hormonal therapy, low body weight, and excessive exercise leading to decreased bone mass can contribute to secondary osteoporosis. Men are reported to have secondary osteoporosis more often than women (Table/Fig 1) (7),(8),(9).
Prevalence
A study done by Gullberg B et al., computed the expected hip fractures for the years 2025 and 2050. The study predicted that by the year 2050, hip fractures would rise to 45%, mainly in Asian countries. Osteoporosis is greatly underdiagnosed and undertreated in Asia, even in the highest-risk patients who have already experienced fractures. This is more prevalent in rural areas of Asian countries, may be due to less accessibility to diagnostic and treatment modalities (10). The International Osteoporosis Foundation; The Asia-Pacific Regional Audit- Epidemiology, costs, and burden of osteoporosis published in 2013 reported that more than 300 million Indians are suffering from osteoporosis-related bone fractures without even understanding that this could double the risk of death (11). By the age of 50, about 50% of Indians have osteopenia, whereas about 10% of the population above the age of 65 is at risk of osteoporotic fracture, and one in every three postmenopausal females is at risk of osteoporotic fracture (12),(13),(14),(15).
According to the National Osteoporosis Foundation, people suffer from about 1.5 million fractures annually (12). A study by Shatrugna V et al., among Indian women aged 30-60 years from a low-income group reported a high prevalence of 52% osteopenia and 29% osteoporosis (16).
Pathophysiology
Primary osteoporosis can be mainly due to age-related factors, including senile osteoporosis, postmenopausal osteoporosis, and idiopathic osteoporosis (17).
1. Senile osteoporosis:
a. Bone marrow mesenchymal stem cells show age-related transformation, leading to the inhibition of osteogenesis, i.e., new bone formation, hence causing excess bone loss.
b. Changes in the microenvironment of the bone due to age-related osteoblast dysfunction can lead to impairment in the differentiation and functions of the osteoblasts.
c. Endocrine dysfunctions are very common in the elderly population. Hormonal deficiencies of oestrogen, testosterone, cortisol, parathyroid, and thyroid, which play a major role in bone metabolism and remodeling, can lead to osteoporosis.
d. Lack of exercise or mobility influences osteoclastic activity, leading to rapid resorption of bone mass.
2. Postmenopausal osteoporosis: Caused mainly by oestrogen deficiency.
a. Inflammation due to oestrogen deficiency is caused by the actions of cytokines (Interleukin-1, Interleukin-17, Interleukin-6, Interleukin-7, Tumour Necrosis Factor-α) on the oestrogen receptors, effectively leading to the inhibition of osteoblasts and promotion of osteoclasts.
b. Receptor Activator of Nuclear Factor-Kappa-B Ligand (RANKL) is necessary for osteoclast development from myeloid precursors. Oestrogen deficiency affects RANKL, leading to the inhibition of osteoclast differentiation and osteoporosis.
3. Idiopathic osteoporosis: Very rare and usually due to genetic mutations.
Signs and Symptoms
Osteoporosis leads to thinning of the cortex, causing fragility of the bones. Hence, fractures can occur in weakened bones even with trivial trauma. Vertebral body fractures are the most common, followed by fractures around the hip and wrist. The maintenance of bone density in our bodies relies on a delicate balance between bone resorption and new bone formation. Total bone mass peaks in an individual around the age of 35. As age increases, this balance is disrupted, leading to increased bone resorption and/or slowed new bone formation, resulting in weakened bones. This imbalance typically begins in a person’s late 30’s, with accelerated bone resorption in postmenopausal women. This process often goes unnoticed until a fracture occurs. Osteoporosis is more common in females due to several reasons: women generally have less bone mass in comparison to men, they tend to live longer, and their calcium intake is usually less. The rate of bone resorption accelerates in postmenopausal women as oestrogen levels fall. The same occurs when a lady undergoes surgical removal of the ovaries, with or without the uterus (14),(15),(16).
Repeated falls may occur due to age-related factors like impaired eyesight, gait disorders, balance disorders (cerebellar pathology), movement disorders (extrapyramidal tract involvement), dementia (Alzheimer’s disease), and sarcopenia (age-related loss of muscle mass). Vertebral body fractures may lead to spine instability, resulting in repeated falls, which can commonly lead to fractures around the hip and wrist joints. Hip fractures require surgical management to prevent complications from prolonged bed rest. Deep vein thrombosis and its complication, pulmonary embolism, are serious complications that can lead to increased mortality. Urinary tract infections, lower respiratory tract infections, malnourishment, protein imbalance, loss of muscle mass, and bedsores are complications that cause higher morbidity in patients with prolonged bed rest following hip fractures. Encouraging the elderly population to walk with support (walking aids), removing obstacles and loose carpets in living rooms, decreasing the height of stairs, and using appropriate footwear may substantially reduce falls (18).
The main issue is the failure to diagnose osteoporosis early, as individuals often do not exhibit specific signs or symptoms. Most of the time, it is diagnosed only after the patient has suffered a fracture or fracture-related complications such as lower limb deformity, chronic backache, reduced height (due to vertebral collapse), or a hunched back (kyphotic deformity). These problems tend to occur after a significant amount of bone calcium has already been lost (19).
Risk Factors for Osteoporosis
Osteoporosis is more common in females, mainly after menopause. Individuals over 65 years old are at an increased risk, as are those with low body weight relative to their height and age. Ethnicity, such as being white or Asian, increases the risk, but African American and Hispanic/Latina women are also at risk, as are those with a history of irregular menstrual cycles or psychiatric illnesses like dementia or anorexia nervosa. Patients with a family history of osteoporosis and fractures are also at a higher risk (20),(21). Patients with a history of long-term use of certain medications, including selective serotonin reuptake inhibitors for treating depression and anxiety, thiazolidinediones (22) glucocorticoids to treat arthritis (23), asthma (24), and lupus (25), antiseizure medicines (26), gonadotropin-releasing hormones for endometriosis (27); proton pump inhibitors containing aluminum that block calcium absorption (28); some cancer treatments (29); too much replacement of thyroid hormone (30); can also contribute to osteoporosis. Smoking, alcohol consumption, a diet low in dairy products or other sources of calcium and vitamin D, and physical inactivity can also contribute as modifiable risk factors for osteoporosis (31) (Table/Fig 2).
Alarming Signs
The warning signs for osteoporosis include a loss of height after puberty, the development of a slumped or hunched posture, back pain with an unspecified cause, women aged 45 or postmenopausal, and a history of repeated fractures. Surprisingly, in 50% of cases, the cause of osteoporosis in men is unknown, while the other 50% is due to age-related bone loss, malabsorption, nutritional deficiencies, chronic alcoholism, smoking, testosterone deficiency, pituitary insufficiency, chronic illnesses (such as chronic renal diseases, hepatic insufficiency, GI malabsorption syndrome, chronic inflammatory polyarthritis, chronic debility, or immobilisation), and tumours. Disuse osteoporosis is common in persons with a sedentary lifestyle (30),(31),(32),(33).
Screening Tools for Osteoporosis
BMD analysis is widely used for screening osteoporosis. Other simple screening tools available include the Osteoporosis Self-assessment Tool for Asians (OSTA), Osteoporosis Risk Assessment Instrument (ORAI), Simple Calculated Osteoporosis Risk Estimation (SCORE), Age-Bulk-one or Never Oestrogen (ABONE), Male Osteoporosis Risk Estimation Score (MORES), and Fracture Risk Assessment Tool (FRAX). These tools can moderately predict the risk of osteoporosis. Complete laboratory assessments, including renal function tests, thyroid function tests, 25-hydroxyvitamin D, and calcium levels, are also done to confirm osteoporosis. However, Dual-energy X-ray Absorptiometry (DEXA) scanning is considered the “gold standard” for diagnosing osteoporosis. Unfortunately, availability is limited in developing countries like India, especially in primary healthcare settings and rural areas. The rate of fractures increases exponentially with the decrease in DEXA score. X-rays are helpful in identifying osteoporosis only in advanced stages (Table/Fig 3) (34),(35),(36),(37).
The WHO recommends DEXA test for assessing BMD. This test can measure calcified tissues, with better specificity than sensitivity compared to other testing modalities for osteoporosis. It takes approximately five minutes of minimal radiation exposure. DEXA provides a t-score and a z-score. The t-score reflects the difference between measured BMD and the mean value of BMD in young adults (37).
Interpretation (3),(38)
a. Normal: T score within one standard deviation of the young adult mean.
b. Osteopenia: scores between -1 and -2.5.
c. Osteoporosis: scores below -2.5 (Table/Fig 4).
The bottom line is, if an individual is 65 or older or has any risk factors as mentioned above, they should get a bone density test done.
Treatment
Non-pharmacological management of osteoporosis: Lifestyle modification should include weight-bearing and muscle-strengthening exercises. A healthy diet with plenty of calcium and vitamin D is prescribed. Treatment for osteoporosis starts with dietary changes. Calcium supplements and oral vitamin D preparations may be given if oral intake is inadequate. The patients are advised to quit smoking cessation and to restrict alcohol intake (39),(40).
The following are dietary recommendations for Bone Health:
1. Calcium: Calcium plays an important role in skeletal mineralisation. More than 99% of the body’s calcium is stored in bone as hydroxyapatite. As per the 2020 guidelines from ICMR-NIN, the dietary recommendations for Indian adults are as follows: 1000 mg/day for adult males and females, pregnant women, and 1200 mg/day for lactating women. For infants, 300 mg/day; children aged 1-3 years, 500 mg/day; children aged 4-6 years, 550 mg/day; children aged 7-9 years, 650 mg/day; boys and girls aged 10-12 years, 850 mg/day; boys and girls aged 13-15 years, 1000 mg/day; and boys and girls aged 16-18 years, 1050 mg/day (40). Other important nutrients include vitamin K, vitamin C, magnesium, zinc, as well as protein to build strong bones (41).
2. Dairy products such as milk, yogurt, and cheese are rich in calcium. Approximately 100 grams of cheese provide 1 gram of calcium, 100 grams of milk provide 100 mg of calcium, and 100 grams of yogurt provide 180 mg of calcium. Fruits like Amla, Guavas, Bananas, Jackfruits, and Chiku, Custard apple are good sources of calcium. Fortified foods can also be important sources of calcium (42),(43),(44),(45).
3. Dry beans including Kidney beans, Black-eyed peas, Chickpeas, Black Peas, Turnip greens, radish, Bottle gourd, Foxnut, chestnuts/chestnuts are good sources of calcium. About 100 grams of cereals usually provide around 30 mg of calcium. Vegetables rich in calcium include kale, broccoli, and watercress, providing between 100 and 150 mg per 100 grams (46).
4. Nuts and Seeds including almonds, sesame, and chia can provide between 250 and 600 mg per 100 g of calcium. Peanuts, groundnuts, walnuts, cashew nuts, almonds, and fruit seeds like melon seeds and watermelon seeds are good sources of calcium (47),(48).
5. Coconut: Coconut, known as a wonder fruit, due to its rich macro- and micronutrient composition and is a vital mineral for bone strength. Coconut milk provides approximately 38 milligrams of calcium per 100 milliliters, and coconut water contains 27.35 mg/100 mL. It is particularly rich in calcium, phosphorus, and magnesium, essential for bone mineralisation and overall bone health. A review published in the Journal of Food Science and Technology highlighted the role of coconut milk in promoting bone health due to its calcium, phosphorus, and magnesium content, which contribute to bone mineralisation and help prevent bone-related disorders. An animal study in the Journal of Medicinal Food demonstrated that supplementing with coconut milk significantly increased BMD and improved bone strength in rats (42),(49),(50).
6. Vitamin D: Vitamin D is essential for the absorption of calcium in bones. It is synthesised in the skin with exposure to sunlight. For individuals with Vitamin D deficiency or limited sun exposure, Vitamin D supplements with 400 to 600 IU per day or 60,000 International Units once a week are prescribed. Foods such as milk, buttermilk, curds, paneer (cottage cheese), cooked eggs, salmon, and vitamin D-fortified milk are good sources of vitamin D (51),(52),(53).
7. Proteins: Dietary protein has a major role in the development and repair of the musculoskeletal system. Proteins break down into essential and non essential amino acids, which are necessary for the synthesis of bone matrix and skeletal muscle proteins. Amino acids also stimulate the gene expression of insulin-like growth factor-1, a hormone that exerts anabolic effects on bone and muscle. Adequate protein consumption is essential for preserving muscle mass and bone health. Non vegetarian sources of protein include lean red meat, chicken, fish, and eggs, which provide first-class and complete protein. Milk and dairy products are also good sources of protein, offering excellent animal protein sources. Vegetarian protein sources include legumes (e.g., lentils, kidney beans), soy products (e.g., tofu), grains, nuts, and seeds, which are considered second-class and incomplete proteins (54),(55),(56).
8. Individuals at risk of osteoporosis should stop smoking and limit alcohol consumption (57),(58).
9. Additionally, for elderly populations, ensure the home is a safe environment to reduce chances of falls. Use proper lighting at home during the night, place a rubber bath mat in the shower or tub to prevent slips, keep floors free from clutter, remove throw rugs that may cause tripping, and use grab bars in the bath or shower to prevent falls and hence decreases the risk of fractures (59).
Pharmacological Treatment of Osteoporosis (Table/Fig 5)
There are plethoras of pharmacological treatment options that work through Antiresorptive or anabolic mechanisms with the aim of reducing the risk of fractures in patients with osteoporosis (60). Pharmacological treatments are broadly classified into two categories:
a. Antiresorptive agents like bisphosphonates, oestrogen agonists, oestrogen antagonists, calcitonin, and denosumab act by slowing down the resorption of bones.
b. Anabolic agents like teriparatide act by strengthening bones and stimulating bone synthesis (61).
In women with known osteoporosis, drugs including risedronate, alendronate, zoledronic acid, or denosumab are used to reduce the risk of fractures. Bazedoxifene, a selective oestrogen receptor modulator combined with conjugated oestrogen, has been approved by the FDA for the prevention of osteoporosis but not for treatment. Hormonal therapy is advised for the prevention and treatment of postmenopausal osteoporosis in asymptomatic postmenopausal women (62),(63),(64).
Bisphosphonates are the first-line therapy for osteoporosis in men (65). The Endocrine Society recommends zoledronic acid for men with a recent hip fracture, risedronate for men at risk for hip fractures, and teriparatide for men at high-risk for fracture (66).
Raloxifene, Ibandronate, and Teriparatide are used if patients are unable to tolerate the above medications. The use of combination therapy with teriparatide and a bisphosphonate or teriparatide and denosumab in patients with severe osteoporosis and hip and vertebral fractures is worth considering (67).
These drugs can also be classified as non nitrogen and nitrogen-containing compounds. The nitrogen-containing compounds inhibit farnesyl pyrophosphate synthase, ultimately inhibiting osteoclast resorption and inducing osteocyte apoptosis.
Commonly used medications include:
- Alendronate, which may reduce the rate of hip, spine, and wrist fractures by 50%.
- Risedronate, which may reduce vertebral and non vertebral fractures by 40% over three years.
- Intravenous zoledronic acid, which reduces the rate of spine fractures by 70% and hip fractures by 40% over three years.
- RANKL inhibitors (denosumab): Denosumab is a monoclonal Ig2 that targets RANKL and inhibits its ability to bind to RANK, resulting in the inhibition of osteoclast activation (68),(69),(70).
Differential Diagnosis
Conditions like homocystinuria, hyperparathyroidism, imaging in osteomalacia and renal osteodystrophy, mastocytosis, multiple myeloma, Paget’s disease, scurvy, and sickle cell anaemia should be considered for differential diagnosis before starting the treatment of osteoporosis (71).
Prognosis of Osteoporosis
Early detection leads to better outcomes. Chronic bone pain and fractures are the outcomes of untreated osteoporosis. Lifestyle modification in terms of healthy diet and exercise have been proven to be useful in preventing osteoporosis. Special emphasis should be given to postmenopausal women and individuals aged 65 and above (72).
Complications: Hip and spinal column fractures are the most common complications of osteoporosis. Falls are the commonest cause of hip fractures, leading to further disability and an increased risk of mortality. Spinal fractures can also occur, and in the absence of patient falls, compression fractures may lead to back pain and a kyphotic posture (73).
Recent advances: Novel therapies include newer selective oestrogen receptor modulators, Cathepsin-K inhibitors, and antisclerostin antibodies. Gene therapy represents the most recent advancement in the management of osteoporosis. Wingless related integration site (WNT)-modulating gene silencers are being explored as a form of gene therapy for osteoporosis and bone fractures (74),(75).
Conclusion
Osteoporosis is a common condition affecting the elderly population and is often diagnosed only after a fragility fracture and its complications, osteoporosis also has psychological and financial impacts on individuals. There are multiple known risk factors that contribute to the development of osteoporosis, hence it best managed by an inter-professional team of healthcare workers. Community education is crucial as many people are unaware of the serious consequences
Reference
|
| | 1. | Kanis JA. Assessment of osteoporosis at the primary health-care level. WHO Scientific Technical Report. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School. 2008. Osteoporosis. p-288. Last accessed on 31-12-2023.
| | 2. | Kanis JA, Harvey NC, McCloskey E, Bruyère O, Veronese N, Lorentzon M, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):01-12.
[ CrossRef] [ PubMed] | | 3. | NIH Consensus Development Panel on: Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-95.
[ CrossRef] [ PubMed] | | 4. | Mohammed ZA, Almeshal MA, Aldawsari SA, Alanazi MA, Alanazi AD, Alqahtani FA, et al. Prevalence of fracture and osteoporosis and awareness of osteoporosis among general population of Majmaah City in 2013. Indo Am JP Sci. 2019;357-61.
| | 5. | Dziedzic K, Hammond A. Chapter 20: Osteoporosis. In: Dowson C and Lewis R (eds). Rheumatology: Evidence-Based Practice for Physiotherapists and Occupational Therapists. Churchill Livingstone; 2010. Pp. 289-305.
[ CrossRef] | | 6. | Sozen T, Ozişik L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46-56.
[ CrossRef] [ PubMed] | | 7. | Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. CMAJ. 2010;182(17):1864-73.
[ CrossRef] [ PubMed] | | 8. | Varacallo MA, Fox EJ. Osteoporosis and its complications. Med Clin North Am. 2014;98(4):817-31.
[ CrossRef] [ PubMed] | | 9. | Varacallo M, Seaman TJ, Jandu JS, Pizzutillo P. Osteopenia. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL): Oct 24; 2022. Available from: https://pubmed.ncbi.nlm.nih.gov/29763053/.
| | 10. | Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407-13.
[ CrossRef] [ PubMed] | | 11. | Mithal A, Bansal B, Kyer CS, Ebeling P. The Asia-Pacific Regional Audit-epidemiology, costs, and burden of osteoporosis in India 2013: A report of International Osteoporosis Foundation. Indian J Endocrinol Metab. 2014;18(4):449-54.
[ CrossRef] [ PubMed] | | 12. | Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. National Osteoporosis Foundation. Clinician’s Guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-81.
[ CrossRef] [ PubMed] | | 13. | Kadam NS, Chiplonkar SA, Khadilkar AV, Khadilkar VV. Prevalence of osteoporosis in apparently healthy adults above 40 years of age in Pune City, India. Indian J Endocrinol Metab. 2018;22(1):67-73.
[ CrossRef] [ PubMed] | | 14. | Kaushal N, Vohora D, Jalali RK, Jha S. Prevalence of osteoporosis and osteopenia in an apparently healthy Indian population - A cross-sectional retrospective study. Osteoporos Sarcopenia. 2018;4(2):53-60.
[ CrossRef] [ PubMed] | | 15. | Ji MX, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med. 2015;1(1):09-13.
[ CrossRef] [ PubMed] | | 16. | Shatrugna V, Kulkarni B, Kumar PA, Rani KU, Balakrishna N. Bone status of Indian women from a lowincome group and its relationship to the nutritional status. Osteoporos Int. 2005;16(12):1827-35.
[ CrossRef] [ PubMed] | | 17. | Rosen CJ, Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al,.The Epidemiology and Pathogenesis of Osteoporosis. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. 2020 Jun 21. Available from: https://pubmed.ncbi.nlm.nih.gov/25905357/.
| | 18. | Melton LJ 3rd, Achenbach SJ, Atkinson EJ, Therneau TM, Amin S. Long-term mortality following fractures at different skeletal sites: A population-based cohort study. Osteoporos Int. 2013;24(5):1689-96.
[ CrossRef] [ PubMed] | | 19. | Carpintero P, Caeiro JR, Carpintero R, Morales A, Silva S, Mesa M. Complications of hip fractures: A review. World J Orthop. 2014;5(4):402-11.
[ CrossRef] [ PubMed] | | 20. | Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville (MD): Office of the Surgeon General (US); 2004. PMID: 20945569.
| | 21. | Van der Voort DJM. Geusens PP, Dinant GJ. Risk factors for osteoporosis related to their outcome: Fractures. Osteoporos Int. 2001;12:630-38.
[ CrossRef] [ PubMed] | | 22. | Kashfi SS, Abdollahi G, Hassanzadeh J, Mokarami H, Khani Jeihooni A. The relationship between osteoporosis and depression. Sci Rep. 2022;12(1):11177.
[ CrossRef] [ PubMed] | | 23. | Lin L, Luo P, Yang M, Wang J, Hou W, Xu P. Causal relationship between osteoporosis and osteoarthritis: A two-sample Mendelian randomized study. Front Endocrinol (Lausanne) 2022;13:1011246.
[ CrossRef] [ PubMed] | | 24. | Wee JH, Min C, Park MW, Byun SH, Lee HJ, Park B, et al. The association of asthma and its subgroups with osteoporosis: A cross-sectional study using KoGES HEXA data. Allergy Asthma Clin Immunol. 2020;16:84.
[ CrossRef] [ PubMed] | | 25. | Barbulescu A, Vreju FA, Criveanu C, Rosu A, Ciurea P. Osteoporosis in systemic lupus erythematosus - Correlations with disease activity and organ damage. Curr Health Sci J. 2015;41(2):109-14. Doi: 10.12865/CHSJ.41.02.04. Epub 2015 Apr 10. PMID: 30364875; PMCID: PMC6201199.
| | 26. | Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr. 2003;3(3):91-95.
[ CrossRef] [ PubMed] | | 27. | Uehara M, Wada-Hiraike O, Hirano M, Koga K, Yoshimura N, Tanaka S, et al. Relationship between bone mineral density and ovarian function and thyroid function in perimenopausal women with endometriosis: A prospective study. BMC Women’s Health. 2022;22:134.
[ CrossRef] [ PubMed] | | 28. | Lespessailles E, Toumi H. Proton pump inhibitors and bone health: An update narrative review. Int J Mol Sci. 2022;23(18):10733.
[ CrossRef] [ PubMed] | | 29. | Drake MT. Osteoporosis and cancer. Curr Osteoporos Rep. 2013;11:163-70.
[ CrossRef] [ PubMed] | | 30. | Delitala AP, Scuteri A, Doria C. Thyroid hormone diseases and osteoporosis. J Clin Med. 2020;9(4):1034.
[ CrossRef] [ PubMed] | | 31. | Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;6:2029-49.
[ CrossRef] [ PubMed] | | 32. | Vilaca T, Eastell R, Schini M. Osteoporosis in men. Lancet Diabetes Endocrinol. 2022;10(4):273-83.
[ CrossRef] [ PubMed] | | 33. | Herrera A, Lobo-Escolar A, Mateo J, Gil J, Ibarz E, Gracia L. Male osteoporosis: A review. World J Orthop. 2012;3(12):223-34.
[ CrossRef] [ PubMed] | | 34. | Prince RL, Lewis JR, Lim WH, Wong G, Wilson KE, Khoo BC, et al. Adding lateral spine imaging for vertebral fractures to densitometric screening: Improving ascertainment of patients at high-risk of incident osteoporotic fractures. J Bone Miner Res. 2019;34(2):282-89.
[ CrossRef] [ PubMed] | | 35. | Khadka B, Tiwari ML, Gautam R, Timalsina B, Pathak NP, Kharel K, et al. Correlates of biochemical markers of bone turnover among post-menopausal women. JNMA J Nepal Med Assoc. 2018;56:754-58.
[ CrossRef] [ PubMed] | | 36. | Rubin KH, Abrahamsen BO, Friis-Holmberg T, Hjelmborg JVB, Bech M, Hermann AP, et al. Comparison of different screening tools (FRAX®, OST, ORAI, OSIRIS, SCORE and age alone) to identify women with increased risk of fracture. A population-based prospective study. Bone. 2013;56(1):16-22.
[ CrossRef] [ PubMed] | | 37. | Cherian KE, Kapoor N, Meeta M, Paul TV. Screening tools for osteoporosis in India: Where do we place them in current clinical care? J Midlife Health. 2021;12(4):257-62.
[ CrossRef] [ PubMed] | | 38. | Koh LK, Sedrine WB, Torralba TP, Kung A, Fujiwara S, Chan SP, et al. A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int. 2001;12(8):699-705.
[ CrossRef] [ PubMed] | | 39. | Unnanuntana A, Gladnick BP, Donnelly E, Lane JM. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92(3):743-53.
[ CrossRef] [ PubMed] | | 40. | ICMR-NIN Expert Group on Nutrient Requirement for Indians, Recommended Dietary Allowances (RDA) and Estimated Average Requirement (EAR) 2020. Available at: https://www.nin.res.in/RDA_Full_Report_2020.html. Last accessed on 12th March 2024.
| | 41. | Body JJ, Bergmann P, Boonen S, Boutsen Y, Bruyere O, Devogelaer JP, et al. Non-pharmacological management of osteoporosis: A consensus of the Belgian bone club. Osteoporos Int. 2011;22(11):2769-88.
[ CrossRef] [ PubMed] | | 42. | Coronado-Zarco R, Olascoaga-Gómez de León A, García-Lara A, Quinzaños-Fresnedo J, Nava-Bringas TI, Macías-Hernández SI. Non-pharmacological interventions for osteoporosis treatment: Systematic review of clinical practice guidelines. Osteoporos Sarcopenia. 2019;5(3):69-77.
[ CrossRef] [ PubMed] | | 43. | Food and Agriculture Organization of the United Nations World Health Organization. Human vitamin and mineral requirements. Report of a joint FAO/WHO expert consultation, Bangkok, Thailand. Food and Nutrition Division, FAO, Rome, 2001:235-47.
| | 44. | Huang F, Wang Z, Zhang J, Du W, Su C, Jiang H, et al. Dietary calcium intake and food sources among Chinese adults in CNTCS. PLoS ONE. 2018;13(10):0205045.
[ CrossRef] [ PubMed] | | 45. | World Health Organization. Vitamin and Mineral Requirements in Human Nutrition. WHO; Geneva, Switzerland: 2004. Vitamin and mineral requirements in human nutritionwho.int). Last accessed on 21st November. (2023). Available from: https://www.who.int/publications/i/item/9241546123.
| | 46. | Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53-58.
[ CrossRef] [ PubMed] | | 47. | Sanwalka NJ, Khadilkar AV, Chiplonkar SA. Development of non-dairy, calcium-rich vegetarian food products to improve calcium intake in vegetarian youth. Current Science. 2011;10:657-63.
| | 48. | Ros E. Health benefits of nut consumption. Nutrients. 2010;2(7):652-82.
[ CrossRef] [ PubMed] | | 49. | Dodevska M, Kukic Markovic J, Sofrenic I, Tesevic V, Jankovic M, Djordjevic B, et al. Similarities and differences in the nutritional composition of nuts and seeds in Serbia. Front Nutr. 2022;9:1003125.
[ CrossRef] [ PubMed] | | 50. | Prakruthi Appaiah L, Sunil PK, Prasanth Kumar AG, Krishna G. Composition of Coconut Testa, Coconut Kernel and its Oil. J Am Oil Chem Soc. 2014;91(6):917-24.
[ CrossRef] | | 52. | Hayatullina Z, Muhammad N, Mohamed N, Soelaiman IN. Virgin coconut oil supplementation prevents bone loss in osteoporosis rat model. Evid Based Complement Alternat Med. 2012;2012:237236.
[ CrossRef] [ PubMed] | | 52. | Laird E, Ward M, McSorley E, Strain JJ, Wallace J. Vitamin D and bone health: Potential mechanisms. Nutrients. 2010;2(7):693-724.
[ CrossRef] [ PubMed] | | 53. | Hill TR, Aspray TJ. The role of vitamin D in maintaining bone health in older people. Ther Adv Musculoskelet Dis. 2017;9(4):89-95.
[ CrossRef] [ PubMed] | | 54. | Voulgaridou G, Papadopoulou SK, Detopoulou P, Tsoumana D, Giaginis C, Kondyli FS, et al. Vitamin D and calcium in osteoporosis, and the role of bone turnover markers: A narrative review of recent data from RCTs. Diseases. 2023;11(1):29.
[ CrossRef] [ PubMed] | | 55. | Bonjour JP. Protein intake and bone health. Int J Vitam Nutr Res. 2011;81(2-3):134-42.
[ CrossRef] [ PubMed] | | 56. | Mangano KM, Sahni S, Kerstetter JE. Dietary protein is beneficial to bone health under conditions of adequate calcium intake: An update on clinical research. Curr Opin Clin Nutr Metab Care. 2014;17(1):69-74.
[ CrossRef] [ PubMed] | | 57. | Zittermann A, Schmidt A, Haardt J, Kalotai N, Lehmann A, Egert S, et al. Protein intake and bone health: An umbrella review of systematic reviews for the evidence-based guideline of the German Nutrition Society. Osteoporos Int. 2023;34(8):1335-53.
[ CrossRef] [ PubMed] | | 58. | Yuan S, Michaëlsson K, Wan Z, Larsson SC. Associations of smoking and alcohol and coffee intake with fracture and bone mineral density: A Mendelian randomization study. Calcif Tissue Int. 2019;105(6):582-88.
[ CrossRef] [ PubMed] | | 59. | Baron JA, Farahmand BY, Weiderpass E, Michaëlsson K, Alberts A, Persson I, et al. Cigarette smoking, alcohol consumption, and risk of hip fracture in women. Arch Intern Med. 2001;161(7):983-88.
[ CrossRef] [ PubMed] | | 60. | Cosman F, de Beur S, LeBoff M, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359-81.
[ CrossRef] [ PubMed] | | 61. | Bhadada SK, Chadha M, Sriram U, Pal R, Paul TV, Khadgawat R, et al. The Indian Society for Bone and Mineral Research (ISBMR) position statement for the diagnosis and treatment of osteoporosis in adults. Arch Osteoporos. 2021;16(1):102.
[ CrossRef] [ PubMed] | | 62. | Meeta M, Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S. Clinical practice guidelines on postmenopausal osteoporosis: An executive summary and recommendations- Update 2019-2020. J Mid-life Health. 2020;11(2):96-112.
[ CrossRef] [ PubMed] | | 63. | Jhaveri S, Upashani T, Bhadauria J, Biswas S, Patel K. Current clinical practice scenario of osteoporosis management in India. J Clin Diagn Res. 2015;9(10):RC04-RC08.
[ CrossRef] [ PubMed] | | 64. | Khadilkar AV, Mandlik RM. Epidemiology and treatment of osteoporosis in women: An Indian perspective. Int J Womens Health. 2015;7:841-50.
[ CrossRef] [ PubMed] | | 65. | Sim IW, Ebeling PR. Treatment of osteoporosis in men with bisphosphonates: Rationale and latest evidence. Ther Adv Musculoskelet Dis. 2013;5(5):259-67.
[ CrossRef] [ PubMed] | | 66. | Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: An Endocrine Society clinical practice guideline. J Clin Endocrinol and Metab. 2012;97(6):1802-22.
[ CrossRef] [ PubMed] | | 67. | Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A review of treatment options. P T. 2018;43(2):92-104.
| | 68. | Tandon VR, Sharma S, Mahajan S, Mahajan A, Khajuria V, Gillani Z. First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates. J Midlife Health. 2014;5(1):29-33.
[ CrossRef] [ PubMed] | | 69. | Lu J, Hu D, Zhang Y, Ma C, Shen L, Shuai B. Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumours, including pharmacological mechanism and clinical trials. Front Oncol. 2023;13:1133828.
[ CrossRef] [ PubMed] | | 70. | Porter JL, Varacallo M. Osteoporosis. [Updated 2023 Aug 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441901/.
| | 71. | Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: Mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139-46.
[ CrossRef] [ PubMed] | | 72. | Taxel P, Kenny A. Differential diagnosis and secondary causes of osteoporosis. Clin Cornerstone. 2000;2(6):11-21.
[ CrossRef] [ PubMed] | | 73. | Ensrud KE, Kats AM, Boyd CM, Diem SJ, Schousboe JT, Taylor BC, et al. Association of disease definition, comorbidity burden, and prognosis with hip fracture probability among late-life women. JAMA Intern Med. 2019;179(8):1095-103.
[ CrossRef] [ PubMed] | | 74. | Tonk CH, Shoushrah SH, Babczyk P, El Khaldi-Hansen B, Schulze M, Herten M, et al. Therapeutic treatments for osteoporosis—which combination of pills. Is the best among the bad? Int J Mol Sci. 2022;23(3):1393.
[ CrossRef] [ PubMed] | | 75. | Dimai HP. New horizons: Artificial intelligence tools for managing osteoporosis. J Clin Endocrinol Metab. 2023;108(4):775-83. [ CrossRef] [ PubMed] |
DOI: 10.7860/JCDR/2024/69058.19248
Date of Submission: Dec 12, 2023
Date of Peer Review: Dec 30, 2023
Date of Acceptance: Feb 07, 2024
Date of Publishing: Apr 01, 2024
AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. Yes
PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: Dec 13, 2023
• Manual Googling: Jan 06, 2024
• iThenticate Software: Feb 05, 2024 (16%)
ETYMOLOGY: Author Origin
EMENDATIONS: 5
|